COMPANY

PepGen Inc

pepgen.com ↗ · New England

Keywords: neurology myotonic dystrophy type 1 Myotonic Dystrophy 1 Duchenne Muscular Dystrophy PGN-EDODM1 PGN-EDO51

Profile checked Oct 10, 2026

Timeline

Dec 23, 2025 Trial start Phase 2: An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) source ↗
Sep 24, 2025 Raise Follow-on offering: $100M (total, as published), announced Sep 24, 2025. Source: SEC filing. source ↗
Dec 17, 2024 Trial start Phase 2: A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment source ↗
Dec 10, 2024 Trial start Phase 2: A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 source ↗
Jan 3, 2024 Trial start Phase 2: A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment source ↗
Dec 12, 2023 Trial start Phase 1: Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 source ↗

2027-03 (ESTIMATED) · Phase 2 · A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 · NCT06667453
2029-01 (ESTIMATED) · Phase 2 · An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) · NCT07220603

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $100.0M. Last 2 years.

Sep 24, 2025 Follow-on offering: $100M (total, as published), announced Sep 24, 2025. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06667453	A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1	Phase 2	Recruiting	Dec 10, 2024	2027-03 (estimated)
NCT07220603	An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)	Phase 2	Recruiting	Dec 23, 2025	2029-01 (estimated)
NCT06204809	Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1	Phase 1	Completed	Dec 12, 2023	Oct 28, 2025 (actual)
NCT06079736	A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment	Phase 2	Terminated	Jan 3, 2024	Aug 28, 2025 (actual)
NCT06833931	A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment	Phase 2	Withdrawn	Dec 17, 2024	May 28, 2025 (actual)